ArticleProceedings of the National Academy of Sciences of the United States of America2024
Germline
Abstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Damage-Associated Molecular Patterns in Mesothelioma: Drivers of Inflammation and Therapeutic Targets.International journal of molecular sciences · 2026Review
- Epidemiological and Prognostic Differences in Malignant Mesothelioma Between Eastern China and SEER Database.Cancer science · 2026Article
- Chromatin accessibility regulates age-dependent nuclear mechanotransduction.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Review
- Clinical and Pathologic Phenotyping of Mesotheliomas Developing in Carriers of Germline BAP1 Mutations.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025Article
- Inhibition of LDHB triggers DNA damage and increases cisplatin sensitivity in pleural mesothelioma.Oncogenesis · 2025Article
- Malignant mesothelioma with a novelOncology letters · 2025Article
- Expanding the Genomic Landscape of HBOC and Cancer Risk Among Mutation Carriers.International journal of molecular sciences · 2025Article
- An overview of BAP1 biological functions and current therapeutics.Biochimica et biophysica acta. Reviews on cancer · 2025Review
- Advances in diagnosis and management of pleural mesothelioma: the Danish clinical guidelines.European clinical respiratory journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Flavia NovelliThoracic Oncology, University of Hawaii Cancer Center, Honolulu, HI 96816.ORCID 0000-0002-3746-7478
Yoshie YoshikawaDepartment of Genetics, School of Medicine, Hyogo Medical University, Hyogo 663-8501, Japan.ORCID 0000-0003-0619-0784
Veronica Angela Maria VittoDepartment of Medical Sciences, Laboratory for Technologies of Advanced Therapies, University of Ferrara, Ferrara 44121, Italy.
Lorenzo ModestiDepartment of Medical Sciences, Laboratory for Technologies of Advanced Therapies, University of Ferrara, Ferrara 44121, Italy.
Michael MinaaiThoracic Oncology, University of Hawaii Cancer Center, Honolulu, HI 96816.ORCID 0000-0002-4397-1507
Sandra PastorinoThoracic Oncology, University of Hawaii Cancer Center, Honolulu, HI 96816.ORCID 0000-0002-4559-1065
Mitsuru EmiThoracic Oncology, University of Hawaii Cancer Center, Honolulu, HI 96816.
Jin-Hee KimThoracic Oncology, University of Hawaii Cancer Center, Honolulu, HI 96816.
Franz KricekNBS-C Bioscience & Consulting GmbH, Vienna 1230, Austria.ORCID 0000-0002-9826-6733
Fang BaiShanghai Institute for Advanced Immunochemical Studies, Shanghai Tech University, Shanghai 201210, China.ORCID 0000-0003-1468-5568
José N OnuchicCenter for Theoretical Biological Physics, Rice University, Houston, TX 77005.ORCID 0000-0002-9448-0388
Angela BononiThoracic Oncology, University of Hawaii Cancer Center, Honolulu, HI 96816.
Joelle S SuarezThoracic Oncology, University of Hawaii Cancer Center, Honolulu, HI 96816.ORCID 0000-0003-1528-2701
Mika TanjiThoracic Oncology, University of Hawaii Cancer Center, Honolulu, HI 96816.
Cristina FavaronThoracic Oncology, University of Hawaii Cancer Center, Honolulu, HI 96816.
Alicia A ZolondickThoracic Oncology, University of Hawaii Cancer Center, Honolulu, HI 96816.ORCID 0000-0002-0818-9632
Ronghui XuThoracic Oncology, University of Hawaii Cancer Center, Honolulu, HI 96816.ORCID 0000-0002-9842-2628
Yasutaka TakanishiThoracic Oncology, University of Hawaii Cancer Center, Honolulu, HI 96816.
Zhanwei WangThoracic Oncology, University of Hawaii Cancer Center, Honolulu, HI 96816.
Greg SakamotoThoracic Oncology, University of Hawaii Cancer Center, Honolulu, HI 96816.
Giovanni GaudinoThoracic Oncology, University of Hawaii Cancer Center, Honolulu, HI 96816.
Joseph GrzymskiDesert Research Institute, Reno, NV 89512.
Federica GrossoMesothelioma Unit, Azienda Ospedaliera Santo Antonio and Santo Biagio (SS) Antonio e Biagio e Cesare Arrigo, Alessandria 15121, Italy.
David S SchrumpThoracic Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1201.
Harvey I PassDepartment of Cardiothoracic Surgery, New York University, New York, NY 10016.ORCID 0000-0003-3222-3471
Lilit AtanesyanDepartment of Oncogenetics, MRC Holland, Amsterdam 1057, the Netherlands.
Jan SmoutDepartment of Oncogenetics, MRC Holland, Amsterdam 1057, the Netherlands.
Suvi SavolaDepartment of Oncogenetics, MRC Holland, Amsterdam 1057, the Netherlands.ORCID 0000-0002-6221-8617
Kavita Y SarinDepartment of Dermatology, Stanford University Medical Center, Stanford, CA 94305.
Hassan AbolhassaniDivision of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 17165, Sweden.ORCID 0000-0002-4838-0407
Lennart HammarströmDivision of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 17165, Sweden.
Qiang Pan-HammarströmDivision of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 17165, Sweden.
Carlotta GiorgiDepartment of Medical Sciences, Laboratory for Technologies of Advanced Therapies, University of Ferrara, Ferrara 44121, Italy.ORCID 0000-0002-2494-7405
Paolo PintonDepartment of Medical Sciences, Laboratory for Technologies of Advanced Therapies, University of Ferrara, Ferrara 44121, Italy.ORCID 0000-0001-7108-6508
Haining YangThoracic Oncology, University of Hawaii Cancer Center, Honolulu, HI 96816.ORCID 0000-0003-1417-2420
Michele CarboneThoracic Oncology, University of Hawaii Cancer Center, Honolulu, HI 96816.ORCID 0000-0001-8928-8474
Funding
Modulating Cancer Stem Cell Signaling in Thoracic MalignanciesZIABC011418 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SCHRUMP, DAVID · 2011 to 2025
$17.4MThe EDRN Mesothelioma Biomarker Discovery LaboratoryU01CA214195 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PASS, HARVEY IRA, YANG, HAINING · 2016 to 2021
$3.5MMechanisms of BAP1 activity in human cancer developmentR01CA237235 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI CARBONE, MICHELE, YANG, HAINING · 2020 to 2024
$2.1MInfluence of germline mutations on susceptibility to environmental carcinogensR01ES030948 · NIEHS · UNIVERSITY OF HAWAII AT MANOA · PI CARBONE, MICHELE, GRZYMSKI, JOSEPH J · 2019 to 2021
$1.9MGermline BAP1 Mutations and Malignant Mesothelioma: Mechanisms and Early DetectionR01CA198138 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI CARBONE, MICHELE · 2015 to 2019
$1.7MLive-Cell Imaging System with TIRF and PhotomanipulationS10OD028515 · OD · UNIVERSITY OF HAWAII AT MANOA · PI FARRAR, CHRISTINE · 2020 to 2020
$382kAROSE, Progetti di Rilevante Interesse Nazionale PRIN20177E9EPYAROSE, Progetti di Rilevante Interesse Nazionale PRIN2017E5L5P3 tEuropean Research Council 853057HHS | NIH | National Cancer Institute (NCI) 1R01CA237235-01A1HHS | NIH | National Institute of Environmental Health Sciences (NIEHS) 1R01ES030948-01Italian Association for Cancer Research IG-19803Italian Association for Cancer Research IG-23670Italian Ministry of Health GR-2013-02356747NCI NIH HHS R01 CA198138NCI NIH HHS R01 CA237235NCI NIH HHS U01 CA214195NIEHS NIH HHS R01 ES030948NIH HHS S10 OD028515NSF PHY-2019745the Early Detection Research Network NCI 5U01CA214195-04US Department of Defence 1R01CA198138Welch Foundation (The Welch Foundation) C-1792
Abstract
We report that ~1.8% of all mesothelioma patients and 4.9% of those younger than 55, carry rare germline variants of the BRCA1 associated RING domain 1 (
Indexed as
Calcium SignalingDNA RepairGenetic Predisposition to DiseaseGerm-Line MutationMesotheliomaTumor Suppressor ProteinsUbiquitin-Protein LigasesApoptosisAsbestosFemaleFibroblastsGenomic InstabilityHumansMaleMiddle AgedTumor Suppressor Protein p53AsbestosBARD1 protein, humanTP53 protein, humanTumor Suppressor Protein p53Tumor Suppressor ProteinsUbiquitin-Protein Ligasescancer preventioncarcinogenesisgene × environmentgeneticsmesothelioma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.